Superseded public profile

In clinical trials↗Metabolic↗

Superseded · version 2: Retatrutide↗

Related names recorded in this version: LY3437943↗

A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. 1

What this version reported

ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.↗

Organizations named in cited records:
  • Eli Lilly and Company↗

Trial records: NCT06297603

Sources for this version

  1. 1
    Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026